More dose,
where you want it,
when you need it
Immediate
Implanted directly into the tumor cavity at the time of resection, GammaTile® initiates radiation therapy when you need it – at the point of lowest tumor burden.
- Eliminates the delay required for post-operative wound healing before starting conventional radiation therapies.1
- Targets the tumor site when the tumor burden is at its lowest, minimizing the risk of tumor progression/recurrence during the traditional treatment gap.1-9
- Provides a single-procedure solution for tumor resection and radiation therapy, reducing patient burden, and ensuring 100% compliance.1
Targeted
Provides highly localized radiation therapy, precisely where you want it.10
- Minimizes radiation exposure to healthy brain tissue, by delivering radiation dose precisely where needed.10
- Ideal for hard-to-treat rapidly growing or previously irradiated tumors, ensuring the maximum dose reaches the tumor bed.2,3,6
- Reduces EBRT side effects such as hair loss.1
Controlled
Efficiently delivers more dose with uniform source distribution, for advanced tumor control.3-10
- Designed to deliver more dose at the source, without passing through healthy brain tissue.1
- Cs-131 seeds with a half-life of 9.7 days ensure the planned dose is given in a shorter period at a higher initial dose rate.11
- Uses collagen tiles as a seed carrier and 3D spacer for uniform source distribution.11
Addressing unmet needs
in brain tumor treatment
Despite technological advances made in EBRT; SRT, IMRT and proton therapy – local control (LC) remains a challenge in the postoperative setting for brain tumors.2,5,6,12-16
Newly Dx Operable Tumors | |||
---|---|---|---|
GBM | Brain Mets | ||
Median PFS | Median OS | LC (1-Year) | |
STANDARD OF CARE | ~6-8 mos13 | ~15-17 mos13 | 60-93%*17-22 |
PFS = Progression-Free Survival
, OS = Overall Survival
, LC = Local Control
* Rates include resection + WBRT, resection + SRS, and resection + WBRT + SRS boost
...tumor recurrence remains
a primary treatment concern
Additional treatment
challenges of
recurrent tumors
Normal brain tissue has often received high doses of radiation during previous EBRT treatments.4,8,9,11
- Adjuvant EBRT is often not utilized or underdosed in this population.4,8,9,11
- Tumor resistance reduces effectiveness and safety of additional EBRT therapy.4,8,9,11
Additional EBRT carries a significant risk of increased radiotoxicity, diminished quality of life, and more financial burden.4,8,9,13
There is no universally defined standard of care for recurrent brain tumors.4,8,9
GammaTile offers increased
local control for your patients with
previously-irradiated brain tumors
Previously-Irradiated Brain Tumors | ||||
---|---|---|---|---|
GBM | Brain Mets | Meningioma | ||
Median PFS | Median OS | LC (1-Year) | Median OS | |
GammaTile | 8.2-11.7 mos7,8 | 24.4-25.0 mos7,8 | 80-100%2,4,5 | 26 mos.9 |
PFS = Progression-Free Survival
, OS = Overall Survival
, LC = Local Control
Toxicity (Previously-Irradiated Brain Tumors)
0-16% Symptomatic radiation necrosis.2,4,5,7,8
0% Reoperation rate due to GammaTile-related radiation necrosis reported in peer-reviewed publications.2,4,5,7,8
The GammaTile Commitment Pledge
for recurrent brain tumors
If a GammaTile treatment of a recurrent brain tumor is canceled because intraoperative pathology reveals only necrotic tissue, we will update the invoice to reflect a $0 charge.*